Fertile ground for cross-border cooperation Even with pan-European EMA approval, pricing is still a country-level issue, with national governments, regional or local stakeholders and pharmaceutical companies being responsible for engaging in price formalities such as negotiations on a bilateral basis. But the landscape in Europe is beginning to show signs of change in how pricing … More Taking stock: European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations
GPI LEAP creates a clear vision for the most ambitious talent by inspiring individuals from diverse backgrounds to come together, grow and succeed in an innovative and dynamic team. We are passionate about growing and developing a world-class, high-performing team of experts through our challenging programme. In an ever-changing global landscape, GPI LEAP shapes careers … More Learn – Engage – Apply – Perform! GPI has launched LEAP; our new career development & training programme
By Preeti Patel and Sophie Schmitz on Oct 3, 2016 We analyze recent changes in Germany’s pharmaceutical legislation & implications for the industry. Germany is typically prioritized by the pharmaceutical industry: it remains a market with relatively high drug prices, offers extensive commercial opportunities and has an important position as an international reference country to … More AMNOG and the German Reforms: What Will Change?